SIGA Technologies, Inc. (SIGA)
| Market Cap | 328.85M |
| Revenue (ttm) | 94.57M |
| Net Income (ttm) | 23.28M |
| Shares Out | 71.64M |
| EPS (ttm) | 0.32 |
| PE Ratio | 14.34 |
| Forward PE | 51.00 |
| Dividend | $0.60 (13.07%) |
| Ex-Dividend Date | Apr 7, 2026 |
| Volume | 275,908 |
| Open | 4.560 |
| Previous Close | 4.560 |
| Day's Range | 4.535 - 4.610 |
| 52-Week Range | 4.290 - 9.620 |
| Beta | 1.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About SIGA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company’s lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York. [Read more]
Financial Performance
In 2025, SIGA Technologies's revenue was $94.57 million, a decrease of -31.82% compared to the previous year's $138.72 million. Earnings were $23.28 million, a decrease of -60.69%.
Financial StatementsNews
Why Are Siga Technologies Shares Trading Higher?
Siga's board of directors declared a special cash dividend of $0.60 per share on the company's common stock. The amount of this dividend is consistent with the special dividend declared last April.
SIGA Declares Special Cash Dividend of $0.60 Per Share
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special ca...
Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.
The first severe case of the virus has been detected in New York.
SIGA Technologies Earnings Call Transcript: Q4 2025
2025 saw $88M in product revenue, $23M net income, and a $155M cash balance with no debt. U.S. and international demand for TPOXX remains strong, with new multi-year contracts and ongoing regulatory engagement in Europe. Capital allocation remains disciplined.
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ...
SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conferenc...
SIGA Technologies Earnings Call Transcript: Q3 2025
Product revenue for the first nine months of 2025 rose to $86 million, with strong U.S. government and international sales. Cash remains robust at $172 million and no debt, supporting ongoing R&D and shareholder returns. Ongoing government engagement and pipeline progress position the company for future growth.
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months end...
SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
SIGA Technologies Earnings Call Transcript: Q2 2025
Q2 2025 saw $79 million in product revenues, strong government funding, and robust net income. Regulatory and international expansion efforts continue, with a solid cash position and no debt. EMA review and U.S. procurement timing remain key uncertainties.
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ende...
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
SIGA Technologies Earnings Call Transcript: Q1 2025
Q1 2025 saw $6M in product revenue, strong international growth, and major U.S. government orders. Cash remains robust at $162M with no debt, and a $0.60 special dividend was declared. Regulatory and pipeline progress continues, with no tariff impact to date.
SIGA Reports Financial Results for Three Months Ended March 31, 2025
Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 Co...
SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference ...
SIGA Appoints Retired General John M. Keane to its Board of Directors
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army Gen...
SIGA Technologies Earnings Call Transcript: Q4 2024
2024 saw record product sales of $133 million, strong profitability, and expanded international reach, including new regulatory approvals and strategic partnerships. Outstanding orders of $70 million are set for 2025 delivery, and a capital management decision is expected in Q2.
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ...
SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conferenc...
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirimat 200 mg capsules), marketed as...
Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analysis of ...
SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product,...
SIGA Technologies Earnings Call Transcript: Q3 2024
Q3 2024 saw strong order momentum and revenue growth, with $53M in nine-month product sales and $146M in outstanding orders. Net income reached $13M for the period, and a robust cash position was maintained. New contracts, pipeline expansion, and global sales drive a positive outlook.
SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...